• Flavopiridol: Pan-CDK Inhibitor Workflows for Cancer Researc

  2026-07-20

  Flavopiridol (L868275) empowers advanced cell cycle arrest and apoptosis studies with its nanomolar CDK inhibition and robust performance in both in vitro and xenograft models. This guide translates recent ER stress insights into actionable protocols, troubleshooting, and comparative advantages—optimizing your cancer research workflows.

• Oligo (dT) 25 Beads: Practical Guidance for mRNA Isolation

  2026-07-20

  Oligo (dT) 25 Beads provide a reliable solution for rapid, selective isolation of eukaryotic mRNA by targeting polyA tails, streamlining workflows for downstream applications such as RT-PCR and next-generation sequencing. They should be used when high-purity mRNA is required from total RNA, but are not suitable for isolation of non-polyadenylated RNA species or prokaryotic RNA.

• Minoxidil Sulphate: Advancing Translational Vascular Researc

  2026-07-19

  This thought-leadership article explores the mechanistic and strategic role of Minoxidil sulphate in translational vascular and renal research. By synthesizing recent pharmacological findings, practical protocol guidance, and the competitive landscape, it offers actionable insight for researchers aiming to bridge preclinical discovery with clinical impact. The discussion is anchored by validated evidence on potassium channel function in sepsis, with a forward-looking assessment of translational opportunities.

• RNA Pol II Inhibition Triggers Apoptosis Beyond Transcriptio

  2026-07-18

  Harper et al. (2025) reveal that inhibition of RNA polymerase II (Pol II) induces cell death via a regulated apoptotic pathway, independent of global transcriptional shutdown. This discovery redefines our understanding of transcription-associated lethality and highlights new mechanistic targets for cancer biology research.

• I-BET151 (GSK1210151A): Practical Lab Use in Cancer Biology

  2026-07-17

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor for research on BRD2, BRD3, and BRD4 function in cancer biology, especially apoptosis and cell cycle arrest assays. It is best suited for controlled, preclinical workflows and should not be used for diagnostics or therapeutic purposes.

• ADRA2A Activation Enhances Carboplatin Sensitivity in Ovaria

  2026-07-17

  This study demonstrates that pharmacological activation of the adrenoceptor alpha-2A (ADRA2A) increases chemosensitivity to carboplatin in ovarian cancer cell lines. The findings suggest a promising drug repositioning strategy using existing ADRA2A agonists to overcome chemoresistance, with implications for future therapeutic development.

• CB-839 (Telaglenastat): Applied Workflows in Cancer Metaboli

  2026-07-16

  CB-839 (Telaglenastat) empowers researchers to dissect glutamine metabolism and splicing vulnerabilities in cancer cells, facilitating robust glutaminolysis inhibition assays and translational drug discovery. This article delivers step-by-step workflow enhancements, troubleshooting strategies, and a deep dive into experimental insights from the latest epitranscriptomic research.

• DiscoveryProbe FDA-approved Drug Library: Redefining Thymic

  2026-07-16

  Explore how the DiscoveryProbe FDA-approved Drug Library empowers advanced screening for thymic regeneration and immune restoration, drawing on breakthrough evidence of drug-induced FOXN1 modulation. Uncover distinct assay strategies and translational opportunities for immune and cancer research.

• Carbapenemase Gene Dynamics in CREC: Insights from Guangdong

  2026-07-15

  This multicenter study systematically characterizes the prevalence, genetic context, and transmission dynamics of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight hospitals in Guangdong, China, during the COVID-19 pandemic. The findings reveal a predominance of plasmid-borne blaNDM-1, high rates of multidrug resistance, and efficient horizontal gene transfer, informing future antimicrobial resistance research and infection control strategies.

• Coronavirus Macrodomain Counters PARP-Mediated Antiviral Def

  2026-07-15

  The referenced study uncovers how the coronavirus macrodomain enables viral replication by reversing host poly (ADP-ribose) polymerase (PARP)-mediated inhibition and limiting interferon (IFN) expression. These findings illuminate specific host-virus interactions and highlight PARP12 and PARP14 as key players in antiviral immunity, providing a foundation for targeted research and therapeutic strategies.

• Wnt-C59 (SKU A8685): Reliable Inhibition of Wnt Secretion in

  2026-07-14

  This article provides a scenario-driven, evidence-based guide to leveraging Wnt-C59 (SKU A8685) as a selective PORCN inhibitor for robust Wnt pathway studies. Addressing real laboratory challenges from assay design to vendor choice, we demonstrate how APExBIO’s Wnt-C59 offers superior reproducibility and validated performance for cell viability, proliferation, and apoptosis research.

• Obeticholic Acid: FXR Agonist Protocols for Liver Fibrosis M

  2026-07-14

  Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid) is redefining translational liver fibrosis research through precise FXR pathway modulation. This guide details experimental workflows, troubleshooting, and actionable protocol enhancements, benchmarking Obeticholic Acid against emerging immunometabolic strategies.

• N2-Alkyl-dG Lesions Promote R-Loop Accumulation and Genome I

  2026-07-13

  This study demonstrates that N2-alkyl-dG DNA lesions induce widespread R-loop accumulation, compromising genome stability by impeding transcription elongation. The findings offer new insight into how alkylation-induced DNA damage contributes to genomic instability and highlight potential therapeutic strategies involving R-loop helicase modulation.

• NPC2 Drives Glioblastoma Malignancy via GPX4-Linked Ferropto

  2026-07-13

  This study identifies Niemann-Pick type C2 (NPC2) as a key regulator of cholesterol metabolism and malignant behavior in glioblastoma (GBM) through its modulation of GPX4-linked ferroptosis. The findings highlight NPC2 as both a prognostic marker and a candidate therapeutic target, with implications for cholesterol-targeting interventions in GBM.

• Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynamics

  2026-07-12

  Mdivi-1 stands out as a selective DRP1 inhibitor, empowering researchers to dissect mitochondrial fission, apoptosis, and neuroprotection with precision. This guide translates recent mechanistic breakthroughs into actionable, workflow-ready protocols and troubleshooting strategies for both cell and animal models.

16280 records 1/1086 page Next 12345 下5页 Last page